Factor D Inhibitors
1 drugsAbout Factor D
Factor D, also known as adipsin, is a serine protease and key component of the alternative pathway of the complement system, part of the innate immune response. It plays a critical role in the complement cascade, influencing inflammatory and autoimmune responses.
Factor D is a therapeutic target due to its role in complement dysregulation, which contributes to inflammatory and autoimmune conditions. Currently, there is no genetic evidence available linking Factor D directly to specific diseases.
VOYDEYA is the only FDA-approved drug targeting Factor D, developed by ALEXION PHARMS INC. It is a small molecule approved in 2024, representing the sole approved modality in this area.
Top Factor D Drugs
ALEXION PHARMS INC is the only company with an approved Factor D targeting drug.
High market concentration suggests significant barriers to entry for new competitors.
Factor D Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Factor D, using small molecule modality.
The absence of other modalities represents a whitespace opportunity for novel biologics.
Factor D Clinical Trials 24 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Factor D. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 14 | 14 | 0 | 0 | 100% |
| Phase 2 | 7 | 5 | 2 | 0 | 71% |
| Phase 3 | 3 | 1 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved Factor D drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Factor D. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Factor D Drug Approval Timeline (2024 - 2024)
The first and most recent drug approval for Factor D was VOYDEYA in 2024.
Recent approval indicates renewed interest, but saturation is low, suggesting growth potential.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 2 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Factor D. A trial counts if an approved drug acting on Factor D is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.